Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04371016
Other study ID # RBHP AUDARD 2019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 30, 2020
Est. completion date January 14, 2021

Study information

Verified date June 2020
Source University Hospital, Clermont-Ferrand
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Acute respiratory distress syndrome (ARDS) is defined using the clinical criteria of bilateral pulmonary opacities on a chest radiograph, arterial hypoxemia (partial pressure of arterial oxygen [PaO2] to fraction of inspired oxygen [FiO2] ratio ≤ 300 mmHg with positive end-expiratory pressure [PEEP] ≥ 5 cmH2O) within one week of a clinical insult or new or worsening respiratory symptoms, and the exclusion of cardiac failure as the primary cause. ARDS is a fatal condition for intensive care unit (ICU) patients with a mortality between 30 and 40%, and a frequently under-recognized challenge for clinicians. Patients with severe symptoms may retain sequelae that have recently been reported in the literature. These sequelae may include chronic respiratory failure, disabling neuro-muscular disorders, and post-traumatic stress disorder identical to that observed in soldiers returning from war. The management of a patient with ARDS requires first of all an optimization of oxygenation, which relies primarily on mechanical ventilation, whether invasive or non-invasive (for less severe patients). Since the ARDS network study published in 2000 in the New England Journal of Medicine, it has been internationally accepted that tidal volumes must be reduced in order to limit the risk of alveolar over-distension and ventilator-induced lung injury (VILI). A tidal volume of approximately 6 mL.kg-1 ideal body weight (IBW) should be applied. Routine neuromuscular blockade of the most severe patients (PaO2/FiO2 < 120 mmHg) is usually the rule, although it is increasingly being questioned. Comprehensive ventilatory management is based on the concepts of baby lung and open lung, introduced respectively by Gattinoni and Lachmann. According to these concepts, it must be considered that the lung volume available for mechanical ventilation is very small compared to the healthy lung for a given patient (baby lung) and that the reduction in tidal volume must be associated with the use of sufficient PEEP and alveolar recruitment maneuvers to keep the lung "open" and limit the formation of atelectasis. In addition to this optimization of mechanical ventilation, it is possible to reduce the impact of mechanical stress on the lung. The prone position, for example, makes it possible to free from certain visceral and mediastinal constraints, to optimize the distribution of ventilation as well as the ventilation to perfusion ratios. Thanks to the technological progress of intensive care beds, it is now possible to verticalize ventilated and sedated patients in complete safety. Verticalization could reduce the constraints imposed to the lungs, by reproducing the more physiological vertical station, and thus modifying the distribution of ventilation. Indeed, in two physiological studies published in 2006 and 2013 in Intensive Care Medicine, 30 to 40% of patients with ARDS appeared to respond to partial body verticalization at 45° and 60° (in a semi-seated or seated position). In addition to improving arterial oxygenation, verticalization appeared to decrease ventilatory stress, related to supine position, and increase alveolar recruitment, with improved lung compliance and end-expiratory lung volume (EELV) over time. Nevertheless, 90° verticalization has never been studied, nor have positions without body flexion (seated or semi-seated). In these studies, only patients with the highest lung compliance appeared to respond. These data support the current hypothesis of subgroups of patients with ARDS with different pathophysiological characteristics (morphological and phenotypic) and therapeutic responses. The investigators hypothesize that verticalization of patients with ARDS improves ventilatory mechanics by reducing the constraints imposed on the lung (transpulmonary pressure), pulmonary aeration, arterial oxygenation and ventilatory parameters. The first objective is to study the influence of the bed position of the patient with early ARDS on the variations in respiratory mechanics represented by the transpulmonary driving pressure (ΔPtp). The second objective is to evaluate changes in ventilatory physiology, tolerance and feasibility of verticalization in patients with early ARDS.


Description:

This is an interventional study evaluating the beneficial impact of verticalization of patients with ARDS on pathophysiological parameters. This therapeutic study aims to test patient's position using dedicated beds (Total Lift Bed™, VitalGo Systems Inc., Arjo AB). The study consists of comparing pulmonary pathophysiological parameters for different positions (from the strict dorsal decubitus to the vertical, with 30° and 60° steps) in patients with early ARDS of focal and non-focal morphologies, under invasive mechanical ventilation. The primary outcome is the difference between the transpulmonary driving pressure (ΔPtp) measured at the end of each verticalization step (30th minute) and the basal value measured at the beginning of the protocol, in strict dorsal decubitus (0°). The minimum number of subjects to enroll in this study is 30 patients with early ARDS, including 15 with focal lung morphology and 15 with non-focal lung morphology. Intermediate analyses are planned every 5 patients in order to reevaluate the needed number of patients. The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes. At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date January 14, 2021
Est. primary completion date January 14, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient with moderate or severe Acute Respiratory Distress Syndrome (ARDS) (PaO2/FiO2 < 200 mmHg), at their early phase (< 12h), under invasive mechanical ventilation with controlled ventilation (intubation or tracheotomy). - Patient equipped with an arterial catheter. - Patient sedated (BIS between 30 and 50) and, if necessary, under neuromuscular blocking agent (TOF < 2/4 at the orbicular) to avoid inspiratory effort. - Patient hemodynamically optimized following the Swan-Ganz catheter data. Exclusion Criteria: - Refusal to participate in the proposed study. - Unavailability of the bed dedicated to verticalization (Total Lift Bed™, VitalGo Systems Inc., Arjo AB) - Obesity with BMI = 35 kg.m-2 - Significant hemodynamic instability defined as an increase of more than 20% in catecholamine doses in the last hour, despite optimization of blood volume, for a target mean blood pressure between 65 and 75 mmHg. - Contraindication to the insertion of a nasogastric tube - Contraindication to the use of the chest electrical impedance tomography - Contraindication to the insertion of a Swan-Ganz catheter - Contraindication to the application of compression stockings - Patient under guardianship - Pregnancy

Study Design


Related Conditions & MeSH terms

  • Acute Lung Injury
  • Acute Respiratory Distress Syndrome
  • Respiratory Distress Syndrome, Adult
  • Respiratory Distress Syndrome, Newborn
  • Syndrome

Intervention

Other:
Verticalization (bed)
The use of a dedicated bed (Total Lift Bed™, VitalGo Systems, Inc., Arjo AB) allows the verticalization of patients under sedation and mechanical ventilation up to 90°. The procedure foresees the gradual verticalization of the patients of 0°, 30°, 60° and 90° by steps of 30 minutes. At the end of each position step (0°, 30°, 60° and 90°), measurement of end-expiratory lung impedance (EELI) and chest electrical impedance tomography (EIT) parameters, measurement of esophageal pressures, collection of ventilatory parameters on the ventilator, collection of Swan-Ganz catheter hemodynamic data, measurement of lung shunt by mixed venous and arterial blood gas analyses and measurement of end-expiratory lung volume (EELV) by the N2 washin-washout method

Locations

Country Name City State
France CHU Clermont-Ferrand

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Transpulmonary driving pressure (?Ptp) Difference between the transpulmonary driving pressure (?Ptp) measured at the end of each verticalization step (30th minute) and the basal value measured at the beginning of the protocol, in strict dorsal decubitus (0°). At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics Maximal transpulmonary pressure (alveolar stress) Baseline
Secondary Pulmonary mechanics Maximal transpulmonary pressure (alveolar stress) At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics Alveolar strain (Vt/EELV) Baseline
Secondary Pulmonary mechanics Alveolar strain (Vt/EELV) At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics Driving pressure Baseline
Secondary Pulmonary mechanics Driving pressure At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics Transpulmonary driving pressure Baseline
Secondary Pulmonary mechanics Transpulmonary driving pressure At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics Dead space (Vd/Vt) Baseline
Secondary Pulmonary mechanics Dead space (Vd/Vt) At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics Pulmonary compliance Baseline
Secondary Pulmonary mechanics Pulmonary compliance At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics Pressure-volume curves Baseline
Secondary Pulmonary mechanics Pressure-volume curves At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics Recruitable volume Baseline
Secondary Pulmonary mechanics Recruitable volume At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics Optimal PEEP (best compliance) Baseline
Secondary Pulmonary mechanics Optimal PEEP (best compliance) At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics O2 consumption (VO2) Baseline
Secondary Pulmonary mechanics O2 consumption (VO2) At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics CO2 production (VCO2) Baseline
Secondary Pulmonary mechanics CO2 production (VCO2) At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics Pulmonary shunt Baseline
Secondary Pulmonary mechanics Pulmonary shunt At the end of each verticalization step (30th minute)
Secondary Pulmonary mechanics Mechanical power imparted to patient's lungs by ventilator Baseline
Secondary Pulmonary mechanics Mechanical power imparted to patient's lungs by ventilator At the end of each verticalization step (30th minute)
Secondary Chest electrical impedance tomography (EIT) Center Of Ventilation (COV) Baseline
Secondary Chest electrical impedance tomography (EIT) Center Of Ventilation (COV) At the end of each verticalization step (30th minute)
Secondary Chest electrical impedance tomography (EIT) Tidal Impedance Variation (TIV) Baseline
Secondary Chest electrical impedance tomography (EIT) Tidal Impedance Variation (TIV) At the end of each verticalization step (30th minute)
Secondary Chest electrical impedance tomography (EIT) Regional Ventilation Delay (RVD) Baseline
Secondary Chest electrical impedance tomography (EIT) Regional Ventilation Delay (RVD) At the end of each verticalization step (30th minute)
Secondary Chest electrical impedance tomography (EIT) End Expiratory Lung Impedance (EELI) Baseline
Secondary Chest electrical impedance tomography (EIT) End Expiratory Lung Impedance (EELI) At the end of each verticalization step (30th minute)
Secondary Chest electrical impedance tomography (EIT) Percentages of over-distended and collapsed alveolar regions. Baseline
Secondary Chest electrical impedance tomography (EIT) Percentages of over-distended and collapsed alveolar regions. At the end of each verticalization step (30th minute)
Secondary Hemodynamics Heart rate Baseline
Secondary Hemodynamics Heart rate At the end of each verticalization step (30th minute)
Secondary Hemodynamics Invasive systolic blood pressure Baseline
Secondary Hemodynamics Invasive systolic blood pressure At the end of each verticalization step (30th minute)
Secondary Hemodynamics Invasive mean blood pressure Baseline
Secondary Hemodynamics Invasive mean blood pressure At the end of each verticalization step (30th minute)
Secondary Hemodynamics Invasive diastolic blood pressure Baseline
Secondary Hemodynamics Invasive diastolic blood pressure At the end of each verticalization step (30th minute)
Secondary Hemodynamics Continuous cardiac output Baseline
Secondary Hemodynamics Continuous cardiac output At the end of each verticalization step (30th minute)
Secondary Hemodynamics Pulmonary systolic arterial pressures Baseline
Secondary Hemodynamics Pulmonary systolic arterial pressures At the end of each verticalization step (30th minute)
Secondary Hemodynamics Pulmonary mean arterial pressures Baseline
Secondary Hemodynamics Pulmonary mean arterial pressures At the end of each verticalization step (30th minute)
Secondary Hemodynamics Pulmonary diastolic arterial pressures Baseline
Secondary Hemodynamics Pulmonary diastolic arterial pressures At the end of each verticalization step (30th minute)
Secondary Hemodynamics Pulmonary vascular resistance Baseline
Secondary Hemodynamics Pulmonary vascular resistance At the end of each verticalization step (30th minute)
Secondary Hemodynamics Pulmonary artery occlusion pressure Baseline
Secondary Hemodynamics Pulmonary artery occlusion pressure At the end of each verticalization step (30th minute)
Secondary Hemodynamics Systolic ejection volume Baseline
Secondary Hemodynamics Systolic ejection volume At the end of each verticalization step (30th minute)
Secondary Hemodynamics SvO2 Baseline
Secondary Hemodynamics SvO2 At the end of each verticalization step (30th minute)
Secondary Hemodynamics End-diastolic volume Baseline
Secondary Hemodynamics End-diastolic volume At the end of each verticalization step (30th minute)
Secondary Hemodynamics Systemic vascular resistance Baseline
Secondary Hemodynamics Systemic vascular resistance At the end of each verticalization step (30th minute)
Secondary Hemodynamics Right ventricular end-diastolic volume Baseline
Secondary Hemodynamics Right ventricular end-diastolic volume At the end of each verticalization step (30th minute)
Secondary Hemodynamics Right ventricular ejection fraction Baseline
Secondary Hemodynamics Right ventricular ejection fraction At the end of each verticalization step (30th minute)
Secondary Blood gases Arterial and mixed venous blood gases data (PaO2, PaCO2, SaO2, SvO2). Baseline
Secondary Blood gases Arterial and mixed venous blood gases data (PaO2, PaCO2, SaO2, SvO2). At the end of each verticalization step (30th minute)
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Recruiting NCT05535543 - Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
Completed NCT04695392 - Restore Resilience in Critically Ill Children N/A
Terminated NCT04972318 - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia N/A
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Completed NCT04078984 - Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
Completed NCT04451291 - Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure N/A
Not yet recruiting NCT06254313 - The Role of Cxcr4Hi neutrOPhils in InflueNza
Not yet recruiting NCT04798716 - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 Phase 1/Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Terminated NCT02867228 - Noninvasive Estimation of Work of Breathing N/A
Not yet recruiting NCT02881385 - Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Withdrawn NCT02253667 - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients N/A
Completed NCT02889770 - Dead Space Monitoring With Volumetric Capnography in ARDS Patients N/A
Completed NCT01504893 - Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia N/A
Withdrawn NCT01927237 - Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide N/A
Completed NCT01680783 - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure N/A
Completed NCT02814994 - Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients N/A